Calidi Biotherapeutics, Inc. Share Price
Equities
CLDI
US3207031010
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1607 USD | +0.44% | -0.80% | -89.36% |
16/04 | Calidi Biotherapeutics Prices $6.1 Million Offering | MT |
21/03 | H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 8.15M 680M |
---|---|---|---|---|---|
Net income 2024 * | -40M -3.34B | Net income 2025 * | -42M -3.5B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.16
x | P/E ratio 2025 * |
-0.26
x | Employees | 41 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.48% |
1 day | +0.44% | ||
1 week | -0.80% | ||
Current month | -71.56% | ||
1 month | -71.69% | ||
3 months | -83.43% | ||
6 months | -93.16% | ||
Current year | -89.36% |
Managers | Title | Age | Since |
---|---|---|---|
Allan Camaisa
CEO | Chief Executive Officer | - | - |
Andrew Jackson
DFI | Director of Finance/CFO | 55 | 30/23/30 |
Amish A. Patel
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Ng
BRD | Director/Board Member | 49 | - |
Alan Stewart
BRD | Director/Board Member | 60 | 10/23/10 |
James Schoeneck
BRD | Director/Board Member | 66 | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.1607 | +0.44% | 886,544 |
25/24/25 | 0.16 | +1.33% | 549,010 |
24/24/24 | 0.1579 | -5.45% | 981,418 |
23/24/23 | 0.167 | +7.05% | 2,055,971 |
22/24/22 | 0.156 | -3.70% | 735,801 |
Delayed Quote Nyse, April 27, 2024 at 01:40 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-89.36% | 8.15M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CLDI Stock